156-Week Outcomes With Aflibercept 8 mg in DME
September 7, 2025 • Retinal Diseases Content Hub
Richard Gale, MBChB, PhD, professor of ophthalmology, Hull York Medical School, UK, presents long-term real-world outcomes of intravitreal aflibercept 8 mg in patients with diabetic macular edema. Over 156 weeks, many eyes showed sustained anatomical improvement and durable reduction in central subfield thickness, with extended treatment intervals and favorable tolerability. These results suggest that higher-dose aflibercept may allow longer intervals between injections while maintaining efficacy in diabetic macular edema.
